Retatrutide: The Triple Agonist GLP-1 Research Guide (2026)
Retatrutide is the GLP-1 compound researchers and weight loss clinicians have been watching most closely since tirzepatide's approval. Phase 2 trial data published in the New England Journal of Medicine showed 24.2% average body weight reduction at 48 weeks -- a figure that outpaced everything that came before it. This guide covers how retatrutide works, what the trial data actually shows, how it compares to semaglutide and tirzepatide, and what researchers sourcing it for laboratory purposes should know.
What Is Retatrutide?
Retatrutide (also designated LY3437943) is a once-weekly injectable peptide developed by Eli Lilly. It is a triple agonist: it activates three distinct receptors simultaneously.
- GLP-1 receptor (glucagon-like peptide-1): reduces appetite, slows gastric emptying, increases insulin secretion in response to food
- GIP receptor (glucose-dependent insulinotropic polypeptide): amplifies insulin response, improves insulin sensitivity, modulates fat storage
- Glucagon receptor: increases energy expenditure, accelerates fat oxidation, acts on the liver to reduce hepatic fat
The first two receptors (GLP-1 and GIP) are also targeted by tirzepatide (Mounjaro/Zepbound). The glucagon component is what sets retatrutide apart. Glucagon receptor activation raises basal metabolic rate and directly mobilizes fat stores, which is why the weight loss numbers from Phase 2 data were notably higher than dual-agonist compounds.
Phase 2 Clinical Trial Results
The key retatrutide trial enrolled 338 adults with obesity or overweight. Participants received weekly injections at one of four dose levels or placebo for 48 weeks. Results published in NEJM in 2023 and updated with extended follow-up data since:
| Dose | Weight Loss at 24 wks | Weight Loss at 48 wks | Responders >15% loss |
|---|---|---|---|
| 1 mg/week | ~5% | ~8.7% | ~20% |
| 4 mg/week | ~10.5% | ~17.5% | ~46% |
| 8 mg/week | ~14.9% | ~22.8% | ~71% |
| 12 mg/week | ~17.5% | ~24.2% | ~83% |
| Placebo | ~-2.1% | ~-2.1% | ~3% |
At the 12mg dose, 26% of participants lost more than 30% of their body weight. The weight loss curve at 48 weeks had not yet flattened, suggesting results would have continued improving with longer treatment.
For context: semaglutide at 2.4mg (Wegovy) produces roughly 15% average weight loss at 68 weeks. Tirzepatide at 15mg (Zepbound) produces roughly 21% at 72 weeks. Retatrutide at 12mg hit 24.2% at 48 weeks -- with the curve still going.
How the Triple Agonist Mechanism Works
Each receptor layer adds a distinct effect. Understanding which does what helps explain the data.
GLP-1 Component
GLP-1 activation reduces appetite through central satiety signaling and delays gastric emptying. This is the same mechanism as semaglutide. Most of the nausea and GI side effects associated with GLP-1 drugs come from this pathway.
GIP Component
GIP amplifies the insulin response to meals and appears to reduce GLP-1-related nausea when co-activated. There is evidence the GIP component in tirzepatide is partly responsible for it having better tolerability than semaglutide at equivalent weight loss levels. Retatrutide carries this benefit as well.
Glucagon Component
The glucagon pathway is where retatrutide diverges from tirzepatide. Glucagon receptor activation:
- Raises basal metabolic rate (thermogenesis)
- Increases fatty acid oxidation in the liver
- Reduces hepatic fat accumulation (relevant for NAFLD/MASH research)
- May preserve lean mass during weight loss compared to GLP-1 alone
The tradeoff is that glucagon activation alone raises blood glucose. The simultaneous GLP-1 and GIP activation counteracts this, keeping glucose levels stable. The three-way balance is what makes the formulation work without causing hyperglycemia.
Retatrutide vs Tirzepatide vs Semaglutide
| Compound | Mechanism | Best published weight loss | FDA status (2026) | Dosing frequency |
|---|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% at 68 weeks | Approved (2021) | Once weekly |
| Tirzepatide (Zepbound) | GIP + GLP-1 dual agonist | ~21% at 72 weeks | Approved (2023) | Once weekly |
| Retatrutide | GIP + GLP-1 + glucagon triple agonist | ~24.2% at 48 weeks | Phase 3 (est. 2026-2027) | Once weekly |
The practical implication: each generation has produced meaningfully better efficacy than the last. Retatrutide's Phase 3 data (due in full by late 2026 or 2027) will determine whether those Phase 2 numbers hold in larger populations.
Side Effect Profile
The most common adverse events in Phase 2 trials were GI-related, consistent with all GLP-1 class compounds:
- Nausea: 42-58% across active dose groups (mild to moderate in most cases)
- Vomiting: 16-26% across active dose groups
- Diarrhea: 18-28%
- Constipation: 10-18%
- Decreased appetite: expected and consistent
GI events were highest in the first 4-8 weeks during titration and decreased over time for most participants. Trial discontinuation due to adverse events was 16% at 12mg, which is higher than tirzepatide but in line with semaglutide at high doses.
Heart rate increase (similar to other GLP-1 compounds) was observed. No serious hypoglycemia events were reported in participants without diabetes.
Research Dosing Protocols from Trial Data
For reference purposes, the Phase 2 trial used the following titration schedules (not a clinical recommendation):
4mg Cohort
- Weeks 1-4: 0.5mg weekly
- Weeks 5-8: 1mg weekly
- Weeks 9-12: 2mg weekly
- Week 13+: 4mg weekly (maintenance)
8mg Cohort
- Weeks 1-4: 0.5mg weekly
- Weeks 5-8: 1mg weekly
- Weeks 9-12: 2mg weekly
- Weeks 13-16: 4mg weekly
- Week 17+: 8mg weekly (maintenance)
12mg Cohort
- Weeks 1-4: 0.5mg weekly
- Weeks 5-8: 1mg weekly
- Weeks 9-12: 2mg weekly
- Weeks 13-16: 4mg weekly
- Weeks 17-20: 8mg weekly
- Week 21+: 12mg weekly (maintenance)
All dosing used subcutaneous injection once weekly. The slow titration schedule is specifically designed to minimize GI adverse events during the adjustment period.
Current Research Applications
Beyond obesity, retatrutide is being investigated for:
- MASH (metabolic dysfunction-associated steatohepatitis): the glucagon component's effect on hepatic fat makes it particularly relevant for liver disease research
- Type 2 diabetes: the triple receptor activation offers a different glycemic control profile than existing GLP-1 agents
- Cardiovascular outcomes: Lilly has initiated CVOT (cardiovascular outcomes trial) alongside Phase 3 weight loss trials
- Lean mass preservation: early research suggests the glucagon component may produce more favorable fat-to-muscle loss ratio compared to GLP-1-only agents
Sourcing Retatrutide for Research
For laboratory research, Pantheon and Amino Club both carry retatrutide with third-party certificates of analysis. Always verify purity documentation before any research use. Research use only -- not for human administration.
What Separates Quality Research Vendors
GLP-1 peptides are more complex to synthesize and verify than simpler peptides like BPC-157 or ipamorelin. A few things to look for when sourcing retatrutide for research:
- Third-party HPLC and mass spec: the COA should come from an independent lab, not just the manufacturer. HPLC purity should be 98%+ for research-grade material.
- Sequence confirmation: mass spectrometry confirms the correct peptide sequence. Without this, you can have high purity of the wrong molecule.
- Endotoxin testing: relevant for any injectable research application. Bacterial endotoxins can produce confounding inflammatory responses in lab work.
- Lyophilized format: retatrutide should be shipped as a lyophilized powder, not pre-reconstituted. Stability in solution is limited compared to dry form.
- Cold chain handling: even lyophilized, proper shipping and storage conditions matter. Vendors should use cold packs and insulated packaging.
For anything GLP-1-class, the COA is the most important document. Read it, verify the issuing lab is real, and confirm the test date is recent (within 6-12 months).
Reconstitution and Storage
Retatrutide reconstitution follows standard peptide protocols:
- Reconstitute with bacteriostatic water (not sterile water) for multi-use vials
- Add solvent slowly down the side of the vial -- do not inject directly onto the powder
- Swirl gently, never vortex or shake vigorously
- Reconstituted solution: store at 2-8C (refrigerator), use within 28 days
- Lyophilized powder: store at -20C for long-term, 2-8C for short-term (up to 3 months)
- Protect from light throughout storage
See the full reconstitution guide for complete protocol and equipment list.
Phase 3 Timeline and What to Watch
Eli Lilly's Phase 3 program (TRIUMPH trials) is running multiple arms:
- TRIUMPH-1: obesity without diabetes (primary endpoint: % body weight change at 48 weeks)
- TRIUMPH-2: obesity with type 2 diabetes
- TRIUMPH-3: MASH with liver fibrosis
- CVOT arm: cardiovascular outcomes in high-risk patients
Initial Phase 3 data readouts are expected in late 2026 and into 2027. FDA review, if initiated promptly after complete data package submission, would put potential approval in the 2027-2028 window depending on priority review designation.
The research community is watching the Phase 3 data closely for two things: whether the 24.2% weight loss from Phase 2 replicates in a larger, more diverse population, and whether the cardiovascular benefit seen with semaglutide (SELECT trial) extends to the triple agonist class.
Frequently Asked Questions
What is retatrutide?
Retatrutide is a once-weekly injectable peptide developed by Eli Lilly that activates three receptors simultaneously: GLP-1, GIP, and glucagon. Phase 2 clinical data showed 24.2% average body weight loss at 48 weeks at the highest dose tested, outperforming all previously published weight loss compounds at comparable timepoints.
How does retatrutide compare to tirzepatide?
Tirzepatide activates GIP and GLP-1 (dual agonist). Retatrutide adds glucagon as a third target. The glucagon component increases energy expenditure and fat oxidation, which researchers believe accounts for the additional weight loss seen versus tirzepatide. In Phase 2 data, retatrutide at 12mg produced roughly 3 percentage points more weight loss than tirzepatide at 15mg at 48 weeks.
What doses were used in retatrutide clinical trials?
The Phase 2 trial tested 1mg, 4mg, 8mg, and 12mg weekly maintenance doses, with a slow titration schedule starting at 0.5mg weekly for all cohorts. The 12mg cohort achieved 24.2% weight loss at 48 weeks. Lower doses (4mg and 8mg) produced 17.5% and 22.8% respectively.
Is retatrutide available yet?
As of mid-2026, retatrutide remains in Phase 3 clinical trials and is not FDA-approved for clinical use. It is available as a research peptide from qualified vendors for laboratory research purposes only. Research use only -- not for human administration.
Where can I source retatrutide for research?
Pantheon and Amino Club both carry retatrutide for research purposes with third-party COAs. Always verify HPLC purity (98%+) and sequence confirmation via mass spec before any research application. For research use only.
What are the main side effects of retatrutide?
In Phase 2 trials, the most common adverse events were GI-related: nausea (42-58%), vomiting (16-26%), diarrhea (18-28%), and constipation (10-18%). Most GI events were mild to moderate and decreased after the titration period. Discontinuation due to adverse events was 16% at the highest dose.